Gainplan’s Nektar Therapeutics NKTR Stock Holding History

Gainplan’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-14,962	Closed	-$1.04M	–	64
2026 Q2	$1.04M	Buy	14,962 +9,962	+199%	+$729K	0.41%	31
2026 Q1	$360K	Sell	5,000 -8,500	-63%	-$484K	0.27%	39
2025 Q4	$571K	Buy	13,500 +8,465	+168%	+$474K	0.21%	33
2025 Q3	$286K	Sell	5,035 -9,965	-66%	-$330K	0.12%	45
2025 Q2	$388K	Buy	+15,000	New	+$168K	0.18%	39

Other funds holding NKTR

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Gainplan's NKTR Position: Q3 2026 in Review

Gainplan sold out of Nektar Therapeutics (NKTR) in Q3 2026, closing a stake of 14,962 shares — an estimated $1.04M sold.

Gainplan first reported a position in NKTR in Q2 2025 and held it in 5 quarters. The position peaked at $1.04M in Q2 2026. 4 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

Gainplan reported no remaining Nektar Therapeutics position as of Q3 2026 after selling out during the quarter.
Gainplan sold 14,962 Nektar Therapeutics shares in Q3 2026, an estimated $1.04M.
Gainplan first reported a position in Nektar Therapeutics in Q2 2025 and held it in 5 quarters.
Gainplan's Nektar Therapeutics position peaked at $1.04M in Q2 2026.
4 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Gainplan's 13F filing for Q3 2026, filed 9 Oct 2026.